Opus Genetics (IRD) Stock Price, News & Analysis

Company Overview

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss or blindness. The company aims to address conditions for which treatment options are limited or unavailable by developing therapies designed to correct or replace disease-causing genetic defects in retinal cells.

Opus Genetics’ pipeline includes investigational programs for genetically defined retinal disorders, including rhodopsin-associated autosomal dominant retinitis pigmentosa and BEST1-related retinal disease. Its programs are intended to use gene therapy approaches to deliver functional genetic material to affected retinal tissues. The company’s assets remain in the research and clinical-development stages and are not broadly marketed commercial products.

Opus Genetics was established in 2021 and has pursued the development of treatments for rare ophthalmic diseases through internal research and collaborations. The company is headquartered in the United States and focuses primarily on advancing potential therapies through preclinical and clinical testing for patients with inherited retinal diseases.

Key Stats

• Today's Range: $5.80 to $6.22
• 50-Day Range: $2.92 to $6.07
• 52-Week Range: $1.35 to $7.07
• Volume: 2.55 million shs
• Average Volume: 4.51 million shs
• Market Capitalization: $493.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.92
• Consensus Rating: Moderate Buy

Opus Genetics Stock Analysis - MarketRank™

Opus Genetics scored higher than 65% of companies evaluated by MarketBeat, and ranked 306th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Opus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 15 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Opus Genetics has a consensus price target of $11.92, representing about 99.7% upside from its current price of $5.97.

Amount of Analyst Coverage

Opus Genetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Opus Genetics are expected to grow in the coming year, from ($0.99) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Opus Genetics is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Opus Genetics is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Opus Genetics has a P/B Ratio of 27.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.95% of the float of Opus Genetics has been sold short.

Short Interest Ratio / Days to Cover

Opus Genetics has a short interest ratio ("days to cover") of 12.43, which indicates bearish sentiment.

Change versus previous month

Short interest in Opus Genetics has recently decreased by 2.99%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Opus Genetics does not currently pay a dividend.

Dividend Growth

Opus Genetics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.52

News Sentiment

Opus Genetics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 37 news articles for Opus Genetics this week, compared to 6 articles on an average week.

Search Interest

10 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

4 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Opus Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $213,749.00 in company stock.

Percentage Held by Insiders

11.70% of the stock of Opus Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

14.97% of the stock of Opus Genetics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IRD
• Previous Symbol: NASDAQ:IRD
• CIK: 1228627
• Web: www.opusgtx.com
• Phone: 248-957-9024
• Fax: 240-268-5310
• Employees: 28
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Opus Genetics: $11.92
• High Price Target: $20.00
• Low Price Target: $7.00
• Potential Upside/Downside: +99.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.59 million
• Net Margins: -1,091.82%
• Pretax Margin: -1,091.82%
• Return on Equity: -338.88%
• Return on Assets: -150.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.19
• Quick Ratio: 12.19

Sales & Book Value

• Annual Sales: $14.20 million
• Price / Sales: 34.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 27.14

Miscellaneous

• Outstanding Shares: 82,650,000
• Free Float: 72,978,000
• Market Cap: $493.42 million
• Optionable: N/A
• Beta: 0.58